4//SEC Filing
Sofinnova Management X, L.L.C. 4
Accession 0001209191-22-003197
CIK 0001868734other
Filed
Jan 12, 7:00 PM ET
Accepted
Jan 13, 4:38 PM ET
Size
15.4 KB
Accession
0001209191-22-003197
Insider Transaction Report
Form 4
Sofinnova Venture Partners X, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2022-01-11$16.00/sh+325,000$5,200,000→ 5,573,949 total(indirect: By Sofinnova Venture Partners X, L.P.) - Conversion
Series A Preferred Stock
2022-01-11−13,571,428→ 0 total(indirect: By Sofinnova Venture Partners X, L.P.)→ Common Stock (3,991,596 underlying) - Conversion
Series B Preferred Stock
2022-01-11−4,275,000→ 0 total(indirect: By Sofinnova Venture Partners X, L.P.)→ Common Stock (1,257,353 underlying) - Conversion
Common Stock
2022-01-11+5,248,949→ 5,248,949 total(indirect: By Sofinnova Venture Partners X, L.P.)
Sofinnova Management X, L.L.C.
10% Owner
Transactions
- Conversion
Series B Preferred Stock
2022-01-11−4,275,000→ 0 total(indirect: By Sofinnova Venture Partners X, L.P.)→ Common Stock (1,257,353 underlying) - Conversion
Common Stock
2022-01-11+5,248,949→ 5,248,949 total(indirect: By Sofinnova Venture Partners X, L.P.) - Conversion
Series A Preferred Stock
2022-01-11−13,571,428→ 0 total(indirect: By Sofinnova Venture Partners X, L.P.)→ Common Stock (3,991,596 underlying) - Purchase
Common Stock
2022-01-11$16.00/sh+325,000$5,200,000→ 5,573,949 total(indirect: By Sofinnova Venture Partners X, L.P.)
Katabi Maha
10% Owner
Transactions
- Conversion
Common Stock
2022-01-11+5,248,949→ 5,248,949 total(indirect: By Sofinnova Venture Partners X, L.P.) - Purchase
Common Stock
2022-01-11$16.00/sh+325,000$5,200,000→ 5,573,949 total(indirect: By Sofinnova Venture Partners X, L.P.) - Conversion
Series A Preferred Stock
2022-01-11−13,571,428→ 0 total(indirect: By Sofinnova Venture Partners X, L.P.)→ Common Stock (3,991,596 underlying) - Conversion
Series B Preferred Stock
2022-01-11−4,275,000→ 0 total(indirect: By Sofinnova Venture Partners X, L.P.)→ Common Stock (1,257,353 underlying)
Footnotes (2)
- [F1]Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO") for no additional consideration, on a 3.4:1 basis, and had no expiration date.
- [F2]The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. Dr. James I. Healy and Dr. Maha Katabi are managing members of SM X and may be deemed to share voting and investment power over the shares held by SVP X. Each of SM X and Dr. Katabi disclaims beneficial ownership of these shares except to the extent of its or her respective pecuniary interest therein. Dr. Healy is a director of the Issuer and files separate Section 16 reports.
Documents
Issuer
CinCor Pharma, Inc.
CIK 0001868734
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001680194
Filing Metadata
- Form type
- 4
- Filed
- Jan 12, 7:00 PM ET
- Accepted
- Jan 13, 4:38 PM ET
- Size
- 15.4 KB